BlackRock Group LTD - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 120 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Group LTD ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2016$243,000
+50.9%
28,025
+10.9%
0.00%
Q3 2016$161,000
+57.8%
25,274
+4.9%
0.00%
Q2 2016$102,000
-3.8%
24,095
-1.6%
0.00%
Q1 2016$106,000
+11.6%
24,489
+58.5%
0.00%
Q4 2015$95,000
+4.4%
15,450
-3.3%
0.00%
Q3 2015$91,0000.0%15,975
+31.3%
0.00%
Q2 2015$91,00012,1670.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q1 2016
NameSharesValueWeighting ↓
Broadfin Capital, LLC 8,951,169$54,871,0003.38%
Virtus ETF Advisers LLC 103,807$636,0001.75%
BKS ADVISORS, LLC 291,150$1,785,0000.92%
Piermont Capital Management Inc. 363,549$2,229,0000.71%
TUDOR INVESTMENT CORP ET AL 2,370,760$14,532,0000.41%
SEARLE & CO. 60,000$349,0000.34%
TURNER INVESTMENTS LLC 252,785$1,550,0000.32%
RICE HALL JAMES & ASSOCIATES, LLC 891,672$5,466,0000.31%
Phocas Financial Corp. 635,333$3,895,0000.30%
TFS CAPITAL LLC 398,283$2,441,0000.26%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders